Osteoprotegerin: A Biomarker in Chronic Kidney Disease.
作者信息
Póvoa Rui
机构信息
Setor de Cardiopatia Hipertensiva da Universidade Federal de São Paulo, São Paulo, SP - Brasil.
Disciplina de Cardiologia da Universidade Federal de São Paulo, São Paulo, SP - Brasil.
出版信息
Arq Bras Cardiol. 2024 Dec 2;121(11):e20240679. doi: 10.36660/abc.20240679. eCollection 2024.
Abstract
摘要
相似文献
1
Osteoprotegerin: A Biomarker in Chronic Kidney Disease.骨保护素：慢性肾脏病中的一种生物标志物。
Arq Bras Cardiol. 2024 Dec 2;121(11):e20240679. doi: 10.36660/abc.20240679. eCollection 2024.
2
Risk Factors Associated With Altered Circulating Micro RNA -125b and Their Influences on Uremic Vascular Calcification Among Patients With End-Stage Renal Disease.与终末期肾病患者循环 microRNA-125b 改变相关的危险因素及其对尿毒症血管钙化的影响。
J Am Heart Assoc. 2019 Jan 22;8(2):e010805. doi: 10.1161/JAHA.118.010805.
3
Association of Serum Osteoprotegerin Level With Myocardial Injury and Cardiovascular Calcification in Chronic Kidney Disease Patients.慢性肾脏病患者血清骨保护素水平与心肌损伤及心血管钙化的相关性
Front Med (Lausanne). 2022 Jun 22;9:814970. doi: 10.3389/fmed.2022.814970. eCollection 2022.
4
Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study).韩国慢性肾脏病患者预后队列研究（KNOW-CKD研究）中未透析慢性肾脏病患者血清骨保护素水平与肾脏预后的关联
Kidney Res Clin Pract. 2022 Mar;41(2):200-208. doi: 10.23876/j.krcp.21.173. Epub 2021 Dec 29.
5
Osteoprotegerin and kidney disease.骨保护素与肾脏疾病。
J Nephrol. 2014 Dec;27(6):607-17. doi: 10.1007/s40620-014-0092-x. Epub 2014 Apr 23.
6
Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study.血清骨保护素水平与慢性肾脏病骨丢失的关联：来自慢性肾脏病知晓研究的见解
PLoS One. 2016 Nov 17;11(11):e0166792. doi: 10.1371/journal.pone.0166792. eCollection 2016.
7
FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart.成纤维细胞生长因子 23 和骨保护素与慢性肾脏病 3 期和 4 期的心肌损伤独立相关。慢性肾脏病-矿物质骨异常与心脏之间的另一个联系。
Nephrol Dial Transplant. 2012 Feb;27(2):727-33. doi: 10.1093/ndt/gfr316. Epub 2011 Jul 12.
8
Circulating osteoprotegerin as a cardiac biomarker for left ventricular diastolic dysfunction in patients with pre-dialysis chronic kidney disease: the KNOW-CKD study.循环骨保护素作为透析前慢性肾脏病患者左心室舒张功能障碍的心脏生物标志物：KNOW-CKD 研究。
Clin Res Cardiol. 2024 Nov;113(11):1555-1564. doi: 10.1007/s00392-024-02382-w. Epub 2024 Feb 6.
9
Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder.血清护骨素检测在慢性肾脏病-矿物质和骨异常早期诊断中的应用。
Nephrology (Carlton). 2011 Aug;16(6):588-94. doi: 10.1111/j.1440-1797.2011.01481.x.
10
Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease.血浆骨保护素是慢性肾脏病患者死亡的独立危险因素及冠状动脉钙化的早期生物标志物。
Clin Chem Lab Med. 2009;47(3):339-46. doi: 10.1515/CCLM.2009.075.
本文引用的文献
1
Osteoprotegerin and Vascular Dysfunction in Patients with Stage 3 Chronic Kidney Disease and Those without Renal Dysfunction: A Case-Control Study.骨保护素与 3 期慢性肾脏病患者和无肾功能障碍患者血管功能障碍的关系：一项病例对照研究。
Arq Bras Cardiol. 2024 Oct;121(11):e20240122. doi: 10.36660/abc.20240122.
2
Metabolic biomarkers and cardiovascular risk stratification in hypertension.高血压患者的代谢生物标志物与心血管风险分层。
Hipertens Riesgo Vasc. 2024 Jul-Sep;41(3):162-169. doi: 10.1016/j.hipert.2024.06.003. Epub 2024 Jul 22.
3
Novel biomarkers in patients with uncontrolled hypertension with and without kidney damage.伴有和不伴有肾脏损伤的未控制高血压患者的新型生物标志物。
Blood Press. 2024 Dec;33(1):2323980. doi: 10.1080/08037051.2024.2323980. Epub 2024 Apr 12.
4
Cardiovascular Risk Prediction in Chronic Kidney Disease.慢性肾脏病中的心血管风险预测。
Am J Nephrol. 2022;53(10):730-739. doi: 10.1159/000528560. Epub 2022 Dec 8.
5
Flow-mediated dilation reference values for evaluation of endothelial function and cardiovascular health.血流介导的扩张参考值用于评估内皮功能和心血管健康。
Cardiovasc Res. 2023 Mar 17;119(1):283-293. doi: 10.1093/cvr/cvac095.
6
Arterial calcifications and osteoprotegerin in chronic hemodialysis patients: impact on 6-year survival.慢性血液透析患者的动脉钙化与骨保护素：对6年生存率的影响
Int Urol Nephrol. 2022 May;54(5):1135-1143. doi: 10.1007/s11255-021-02988-3. Epub 2021 Sep 9.
7
Precision medicine approaches for diabetic kidney disease: opportunities and challenges.精准医学方法在糖尿病肾病中的应用：机遇与挑战。
Nephrol Dial Transplant. 2021 Jun 22;36(Suppl 2):3-9. doi: 10.1093/ndt/gfab045.
8
Biomarker definitions and their applications.生物标志物的定义及其应用。
Exp Biol Med (Maywood). 2018 Feb;243(3):213-221. doi: 10.1177/1535370217750088.
9
Precision Medicine from a Public Health Perspective.从公共卫生角度看精准医学。
Annu Rev Public Health. 2018 Apr 1;39:153-168. doi: 10.1146/annurev-publhealth-040617-014158. Epub 2017 Nov 20.
10
Vascular Calcification and Osteoprotegrin in Chronic Kidney Disease.慢性肾脏病中的血管钙化与骨保护素
Am J Nephrol. 2017;46(1):37-38. doi: 10.1159/000477381. Epub 2017 Jun 15.
Zotero 插件